



Biolnvent

**UNLEASHING IMMUNITY
TO FIGHT CANCER**

Annual General Meeting

Martin Welschhof, CEO

May 3, 2024

FORWARD-LOOKING STATEMENT

This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in BioInvent International AB ("**BioInvent**"). Neither shall the presentation or any part of it, nor the fact of its distribution or communication, form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation thereto.

This presentation contains forward-looking statements, which are subject to risks and uncertainties because they relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. All statements other than statements of historical fact included in this presentation are forward-looking statements. Forward-looking statements give BioInvent's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of BioInvent or the industry in which it operates, to be materially different than any future results, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. BioInvent will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

The information included in this presentation may be subject to updating, completion, revision and amendment and such information may change materially. No person, including BioInvent and its advisors, is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. Neither BioInvent nor any of its owners, affiliates, advisors or representatives (jointly the "**Disclosers**") make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. None of the Disclosers accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.

By attending this presentation or by accepting any copy of this document, you agree to be bound by the foregoing limitations.

BIOINVENT IS FOCUSED ON NOVEL TREATMENTS OF CANCER

In brief

Translating
complex cancer biology
into
innovative antibody therapies

6

Clinical programs



Six expanding clinical programs. Integrated research engine, functional screening and in-house GMP manufacturing.

10+

Partnership agreements



Technology validating deals with Exelixis, Pfizer, Daiichi Sankyo, Bayer, Mitsubishi Tanabe, Takeda, Genentech. Partnering/deal making a key element in business model.

22

Nationalities



Headquarters in Lund, Sweden. 109 employees, 22 nationalities.

65%

International ownership



Strong international shareholder base. Major owners Redmile, Van Herk Investments, Forbion, HBM, Omega, AP4, Invus, Swedbank Robur, Handelsbanken.

1,219

SEKm in liquid funds etc
March 31, 2024 ~112 USDm




Well funded through multiple value inflection points. Listed on NASDAQ OMX Stockholm Mid Cap (BINV).

OUR SUCCESS FACTORS

Success
factors

BioInvent has one of the most exciting and unique cancer immunotherapy pipelines of any European biotech company



DISCOVERY ENGINE

Our proprietary **high-quality antibody library** and animal models deliver candidates ready for clinical development



TOP EXPERTISE

Everything we do is based on our **extensive knowledge** of immunology, cancer biology, and antibody biology



INNOVATIVE R&D

We have **integrated** drug development capabilities, from **early discovery**, **manufacturing** to **trial execution**

USING PARTNERSHIPS TO VALIDATE OUR CAPABILITIES AND EXPERTISE

Partners



Exclusive license agreement and clinical collaboration for BI-1206 for China/Hong Kong/Macau/Taiwan



Co-developing (50/50 share of costs and profits) of oncolytic virus BT-001 for solid tumors, leveraging BioInvent's n-CoDeR® and F.I.R.S.T™ platforms



Clinical supply (pembrolizumab) **and collaboration agreement** with MSD for BI-1206, BI-1808, BI-1910 and BT-001. **Supply** (Calquence®) **agreement** with AstraZeneca for BI-1206.



Mitsubishi Tanabe




Antibody discovery partnerships using n-CoDeR® antibody library (antibodies in clinical development)



Academic/Patient organizations collaborations

LOOKING BACK AT AN EVENTFUL 2023



STRONG PROPRIETARY CLINICAL PIPELINE WITH MULTIPLE VALUE DRIVERS

TNFR2

Study number	Study arm	Primary indication	Discovery	Preclinical	Phase 1	Phase 2	Partner
NCT04752826	BI-1808 single agent	Solid tumors/TCL					
	BI-1808 + pembrolizumab	Solid tumors/TCL					
NCT06205706	BI-1910 single agent	Solid tumors					
	BI-1910 + pembrolizumab	Solid tumors					

FcyRIIB

Study number	Study arm	Primary indication	Discovery	Preclinical	Phase 1	Phase 2	Partner
NCT03571568	BI-1206 + rituximab	NHL (MCL, MZL, iFL)					CASI ¹
	BI-1206 + rituximab + Calquence®	NHL (MCL, MZL, iFL)					
NCT04219254	BI-1206 + pembrolizumab	Solid tumors					CASI ¹
NCT05555251	BI-1607	Solid tumors					

CTLA-4

Study number	Study arm	Primary indication	Discovery	Preclinical	Phase 1	Phase 2	Partner
NCT04725331	BT-001 + pembrolizumab	Solid tumors					transgene ²

Completed
 Ongoing
 Planned


¹ Licensed to CASI for China, Hong Kong, Macau and Taiwan

² 50/50 co-development collaboration with Transgene

Robust partial response (PR) observed in a patient with GIST

Phase 1 data presented at SITC Nov 2023

- All subjects had advanced solid tumors (21 evaluable)
- **Heavily pretreated** patient population, tumor types known to respond poorly to checkpoint inhibitor therapy
- **Stable disease** observed in 7 patients
- PK/PD data enabled identification of a **wide dose range** with complete target coverage
- **Excellent safety** with no DLTs: MTD was not reached



Patient case:


55-year-old male patient with **GIST**. Patient presented with clinically progressive disease for more than 6 months, with multiple metastatic lesions despite **12 prior lines of treatment**. Patient still on treatment.

WHAT'S NEXT?

- Initial Phase 2a single agent update at ASCO, more data YE 2024E
- Phase 1 data for BI-1808 + pembrolizumab (Keytruda) at ASCO

A differentiated, agonist approach to treating solid tumors compared to BI-1808

- Enrolment ongoing in Phase 1/2a clinical trial in the US and Europe since December 2023
- Innovative, **adaptive clinical trial** design for dose escalation
- First part evaluates **single agent** BI-1910
- Second part a dose escalation phase with BI-1910 in combination with **pembrolizumab**. Supply agreement with MSD*
- Exploratory expansion cohorts are then planned in **hepatocellular carcinoma (HCC)** and **non-small cell lung cancer (NSCLC)**.



Preclinical data showcase BI-1910 anti-tumor activity and synergy with anti-PD-1. Further mode-of-action analyses demonstrate that BI-1910 increases intratumoral CD8+ T effector cells and induces long-lasting T cell memory.


WHAT'S NEXT?

- Initial Phase 1 single agent data YE 2024E

Quality of responses particularly impressive Interim results from IV

(June 2023):

- **4 Complete Responses (CR), 3 Partial Responses (PR) and 4 cases of stable disease (SD)**
- **CR:s** have been **long-lasting**, three of them **lasting years after** end of treatment
- As of June 2023, the median duration of complete response was 2.5 years, with three patients ongoing
- **No safety or tolerability concerns**
- No maximum tolerated dose has been defined



BI-1206 IN NHL: POSITIVE INTERIM CLINICAL EFFICACY DATA FROM STUDY IN CHINA




FcγRIIB
BI-1206 +
ritux

CASI Phase 1 dose- escalation data re-inforce previously reported positive efficacy data

(March 2024):

- **1 Complete Responses (CR), 4 Partial Responses (PR)** out of 8 evaluable patients
- **CR** (in Marginal Zone Lymphoma (MZL) has been **long-lasting**, 20+ weeks
- **Manageable safety profile across all patients**



**Durable
complete
remission
(20 + weeks)**

CASI Pharmaceuticals Phase 1 interim data show responses from
5 patients out of 8 evaluable patients

BI-1206 in combination with rituximab and Calquence

- **AstraZeneca** to provide **Calquence** (BTK inhibitor) for combination with BI-1206 and rituximab in the ongoing Phase 1/2a clinical study for the treatment of patients with follicular lymphoma who have progressed or are refractory to rituximab
- The **Phase 2a IV dose expansion cohort** in combination with rituximab is currently enrolling patients, and it will look to enroll patients to be treated with the triplet
- The Calquence expansion cohort is expected to enroll approximately 30 patients at sites in Sweden, Spain, the US, and Brazil

WHAT'S NEXT?

- **BI-1206 SC Phase 1 data H1 2024E**
- **Initial Phase 2a triplet data YE 2024E**



About us Clinical programs Our Science Partners Investors

BioInvent to evaluate BI-1206 in combination with rituximab and Calquence

09 Feb 2024

- **Clinical supply agreement with AstraZeneca to support Phase 1/2a BI-1206 combination study**
- **BI-1206 to be evaluated in combination with Calquence® and rituximab in Phase 1/2a trial in non-Hod-**
- **The ongoing rituximab combination trial will be expanded to include the triplet arm**

Lund, Sweden – February 9, 2024 – BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announce a clinical supply agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate BioInvent's anti-FcγRIIB antibody, BI-1206, in combination with Calquence (acalabrutinib), in a Phase 1/2a study in non-Hodgkin's lymphoma (NHL).

Under the terms of the supply agreement, AstraZeneca will provide Calquence, a selective inhibitor of Bruton's tyrosine kinase, in combination with BI-1206 and rituximab in the ongoing Phase 1/2a clinical study (NCT03571568) for the treatment of patients who have progressed or are refractory to rituximab.

"Having already shown the benefits of combining BI-1206 with rituximab, we believe the addition of Calquence for the triplet combination will improve clinical outcomes for patients with non-Hodgkin's lymphoma, including follicular lymphoma and mantle cell lymphoma," said Dr. Welschof, CEO of BioInvent. "We are extremely pleased to be entering into this supply agreement with AstraZeneca to bring a new, chemo-free, treatment option for these patients."

The Phase 1 part - intravenously (IV) administered BI-1206 - has been completed with impressive early signs of clinical activity. The Phase 1 expansion cohort is currently enrolling patients, and it will look to enroll patients to be treated with the triplet. A subcutaneous (SC) version of BI-1206 is also being developed in parallel to the IV and it is expected to bring a great deal of convenience to the treatment. The Calquence expansion cohort is expected to enroll approximately 30 patients at sites in Sweden, Spain, the US, and Brazil.

BI-1206 IN SOLID TUMORS: POSITIVE INTERIM CLINICAL PHASE 1 RESULTS

FcγRIIB
BI-1206 +
pembro

Early signs of efficacy in BI-1206 IV + pembrolizumab Phase 1

(June 2023):

- All patients enrolled had received **at least one prior line of anti-PD1/PDL1** therapy
- **18** evaluable **patients** in IV arm (6/2023)
- **No major safety concerns**
- **Two long-lasting partial responses (PR)** and **two** patients with **stable disease (SD)**
- Both responding patients had **melanoma**, and both had progressed after prior checkpoint inhibitor treatments



WHAT'S NEXT?

- Further BI-1206 + pembrolizumab Phase 1 data at ASCO

BT-001: SINGLE AGENT PHASE 1 DATA OPENS FOR COMBINATION

CTLA-4
BT-001

Objective antitumor activity, i.e. decrease of injected lesion size of $\geq 50\%$ observed in two patients

Data from Phase 1/2a open-label, multicenter, dose-escalation study of BT-001 as single agent


- Treatment of all **Phase 1** cohorts in monotherapy completed with **no safety concerns**
- **Stabilization of injected lesions** in 11/18 patients
- In October 2023, BioInvent and Transgene announced first patient dosed in the Phase 1 part B clinical trial evaluating the **combination** of **BT-001** and MSD's anti-PD-1 therapy, KEYTRUDA® (**pembrolizumab**)



WHAT'S NEXT?

- **First Phase 1 data BT-001 + pembrolizumab combination H2 2024**

EXPECTED KEY CLINICAL MILESTONES 2024





BioInvent

www.bioinvent.com

Follow us

